- Numinus Wellness (NUMI) has completed the acquisition of Novamind Inc.
- Numinus now operates 13 wellness clinics, four clinical research facilities and a dedicated psychedelics research lab
- Numinus Founder and CEO Payton Nyquvest sat down with Coreena Robertson to discuss the news
- Numinus also announced the appointments of Dr. Reid Robison as Chief Clinical Officer and Dr. Paul Thielking as Chief Science Officer
- Numinus Wellness Inc. (NUMI) opened trading at C$0.365
Numinus Wellness (NUMI) has completed the acquisition of Novamind Inc. following shareholder and court approvals
Numinus now operates 13 wellness clinics, four clinical research facilities and a dedicated psychedelics research lab – positioning the company as a leading integrated mental wellness company providing ketamine- and psychedelic-assisted therapies.
Numinus Founder and CEO Payton Nyquvest sat down with Coreena Robertson to discuss the news.
“This acquisition elevates our collective service offering, and we look forward to helping an even greater number of people access effective and safe treatments to support mental wellness. We warmly welcome the Novamind team to Numinus and believe our shared values and focus on client service will ensure a seamless integration as we continue to grow as one unified company.”
Numinus also announced the appointments of Dr. Reid Robison (MD) as Chief Clinical Officer and Dr. Paul Thielking (MD) as Chief Science Officer, both from Novamind.
Numinus Wellness Inc. is a mental health and wellness company.
Numius Wellness Inc. (NUMI) opened trading at C$0.365.